REDWOOD CITY, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast ...
REDWOOD CITY, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast ...
REDWOOD CITY, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing investigational medicine lirentelimab (AK002) for the treatment ...
Please provide your email address to receive an email when new articles are posted on . Lirentelimab was safe and effective in the long-term treatment of patients with eosinophilic gastritis and/or ...
Infectious complications of CD20 x CD3 bispecific antibody therapy in patients with B-cell lymphoma. Real-life use of G-CSF in non-small cell lung cancer (NSCLC): Secondary data analysis from the ...
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results